Publication:
Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer.

Simple item page
dc.contributor.authorMartin-Blazquez, Ariadna
dc.contributor.authorDíaz, Caridad
dc.contributor.authorGonzalez-Flores, Encarnacion
dc.contributor.authorFranco-Rivas, Daniel
dc.contributor.authorJimenez-Luna, Cristina
dc.contributor.authorMelguizo, Consolacion
dc.contributor.authorPrados, Jose
dc.contributor.authorGenilloud, Olga
dc.contributor.authorVicente, Francisca
dc.contributor.authorCaba, Octavio
dc.contributor.authorPerez-Del-Palacio, Jose
dc.contributor.funderFundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO)
dc.contributor.funderRoche Pharma S.L.
dc.contributor.funderMerck Sharp & Dohme de España S.A.
dc.contributor.funderUniversity of Granada
dc.contributor.funderAndalusian Regional Government
dc.date.accessioned2023-02-08T14:38:55Z
dc.date.available2023-02-08T14:38:55Z
dc.date.issued2019-12-27
dc.description.abstractColorectal cancer is one of the main causes of cancer death worldwide, and novel biomarkers are urgently needed for its early diagnosis and treatment. The utilization of metabolomics to identify and quantify metabolites in body fluids may allow the detection of changes in their concentrations that could serve as diagnostic markers for colorectal cancer and may also represent new therapeutic targets. Metabolomics generates a pathophysiological 'fingerprint' that is unique to each individual. The purpose of our study was to identify a differential metabolomic signature for metastatic colorectal cancer. Serum samples from 60 healthy controls and 65 patients with metastatic colorectal cancer were studied by liquid chromatography coupled to high-resolution mass spectrometry in an untargeted metabolomic approach. Multivariate analysis revealed a separation between patients with metastatic colorectal cancer and healthy controls, who significantly differed in serum concentrations of one endocannabinoid, two glycerophospholipids, and two sphingolipids. These findings demonstrate that metabolomics using liquid-chromatography coupled to high-resolution mass spectrometry offers a potent diagnostic tool for metastatic colorectal cancer.
dc.description.sponsorshipThis study was supported by a grant (n° 15CC056/DTS17/00081- ISCIII-FEDER) from the Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO) and Roche Pharma S.L. Authors from the Fundación MEDINA acknowledge the receipt of financial support from this public-private partnership of Merck Sharp & Dohme de España S.A. with the University of Granada and Andalusian Regional Government (PIN-0474-2016).
dc.description.versionSi
dc.identifier.citationMartín-Blázquez A, Díaz C, González-Flores E, Franco-Rivas D, Jiménez-Luna C, Melguizo C, et al. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer. Sci Rep. 2019 Dec 27;9(1):20198.
dc.identifier.doi10.1038/s41598-019-55952-8
dc.identifier.essn2045-2322
dc.identifier.pmcPMC6934557
dc.identifier.pmid31882610
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934557/pdf
dc.identifier.unpaywallURLhttps://www.nature.com/articles/s41598-019-55952-8.pdf
dc.identifier.urihttp://hdl.handle.net/10668/14895
dc.issue.number1
dc.journal.titleScientific reports
dc.journal.titleabbreviationSci Rep
dc.language.isoen
dc.organizationIBS
dc.page.number9
dc.provenanceRealizada la curación de contenido 29/07/2025.
dc.publisherNature Publishing Group
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.relation.projectID15CC056/DTS17/00081- ISCIII-FEDER
dc.relation.projectIDPIN-0474-2016
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-019-55952-8
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectMetabolomic signature
dc.subjectMetastatic colorectal cancer
dc.subjectUntargeted metabolomics
dc.subjectLiquid‑chromatography mass spectrometry
dc.subjectEndocannabinoid
dc.subjectGlycerophospholipid
dc.subject.decsMetabolómica
dc.subject.decsCáncer colorrectal metastásico
dc.subject.decsMetabolómica no dirigida
dc.subject.decsEspectrometría de masas acoplada a cromatografía líquida
dc.subject.decsEndocannabinoides
dc.subject.decsGlicerofosfolípidos
dc.subject.meshBiomarkers, Tumor
dc.subject.meshCase-Control Studies
dc.subject.meshChromatography, Liquid
dc.subject.meshColorectal Neoplasms
dc.subject.meshEnergy Metabolism
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMass Spectrometry
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.titleUntargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number9
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
PMC6934557.pdf
Size:
1.92 MB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
Martin-Blazquez_UntargetedLC-HRMS-based_MaterialSuplementario.docx
Size:
100.65 KB
Format:
Microsoft Word XML
Download

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía